USP7通过稳定JunD激活AIFM2抑制黑色素瘤铁死亡
本研究探讨USP7-JunD-AIFM2通路在黑色素瘤细胞铁死亡抵抗中的调控机制。USP7作为去泛素化酶稳定转录因子JunD,JunD促进AIFM2(FSP1)表达,增强铁死亡抵抗。抑制USP7导致JunD降解和AIFM2水平降低,在体外和小鼠异种移植模型中使黑色素瘤细胞对铁死亡敏感。
要点
- USP7去泛素化稳定JunD,进而上调AIFM2表达
- USP7-JunD-AIFM2通路介导黑色素瘤铁死亡抵抗
- 抑制USP7可降解JunD、降低AIFM2并增敏铁死亡
核心结论
- USP7-JunD-AIFM2通路是黑色素瘤铁死亡抵抗的关键调控机制,靶向USP7可能为耐药黑色素瘤提供治疗策略。
研究设计与样本
- 基础研究,探讨USP7-JunD-AIFM2通路调控黑色素瘤铁死亡抵抗的机制,并在体外及小鼠异种移植模型中验证。
主要发现
- USP7被鉴定为稳定转录因子JunD的关键去泛素化酶。
- 稳定的JunD促进AIFM2(FSP1)表达,增强黑色素瘤铁死亡抵抗。
- 抑制USP7导致JunD降解和AIFM2水平降低,在体外和小鼠异种移植模型中有效增敏黑色素瘤细胞对铁死亡。
临床怎么用
- 靶向USP7可能作为克服黑色素瘤铁死亡抵抗的潜在治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ferroptosis resistance in melanoma cells is a key factor in melanoma progression, influenced by the tumor microenvironment. This study investigates the regulatory mechanisms of the USP7-JunD-AIFM2 pathway, which contributes to ferroptosis resistance in melanoma cells. We identified USP7 as a critical deubiquitinase that stabilizes the transcription factor JunD. Stabilized JunD, in turn, promotes the expression of AIFM2 (also known as FSP1), enhancing ferroptosis resistance in melanoma. Inhibition of USP7 led to JunD degradation and reduced AIFM2 levels, effectively sensitizing melanoma cells to ferroptosis both in vitro and in murine xenograft models. These findings underscore the role of the USP7-JunD-AIFM2 pathway in ferroptosis resistance and suggest that targeting USP7 could provide a potential therapeutic strategy against resistant melanoma.
引用
- Xie J, Ma C, Zhao S, et al. Deubiquitination by USP7 Stabilizes JunD and Activates AIFM2 (FSP1) to Inhibit Ferroptosis in Melanoma. J Invest Dermatol. 2025. PMID: 40187679. doi:10.1016/j.jid.2025.03.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。